TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND), a leading biotech company in fast-acting psychedelics is pleased to announce that it has filed a patent application in the United States Patent and Trademar
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO--(BUSINESS WIRE)--$HMPS #cannabis--Hempsana Holdings Ltd. (the
Health-care industry leader poised to accelerate the Company’s global growth plans MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corporation (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce
MONTRÉAL--(BUSINESS WIRE)--The organizers are pleased to announce that the Sweet Pharma Day’s 2nd edition, will be held on October 7, 2021, in a virtual format. This unique, invitation-only event is inviting young Canadian biotechs to submit their appl
First 143 patients enrolled in the pivotal Phase 3 trial, with top-line results from interim analysis expected later this year Enrollment of patients in the REVERSE-IT trial requiring urgent surgery or invasive procedure now complete, with trial focus s
GreenGene F Now approved in China, provides more hemophilia A patients access to proven therapy YONGIN, South Korea--(BUSINESS WIRE)--GC Pharma (006280.KS) today announced the approval of GreenGene F (Beroctocog alfa) [Recombinant Human Coagulation
- The results of the trial demonstrate the efficacy, safety and tolerability of GC5107 in patients with PI YONGIN, South Korea--(BUSINESS WIRE)--GC Pharma (006280.KS) today announced that Frontiers in Immunology has published the safety and final efficac
Company Exceeds Preliminary Guidance with its Second Consecutive Quarter of Record Revenue LAS VEGAS & TORONTO--(BUSINESS WIRE)--Flower One Holdings Inc. (“Flower One” or the “Company”) (CSE: FONE) (OTCQX: FLOOF) (FSE: F11), the leading cannabis
- The Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials are on track, with topline results expected in Q4 2021 - LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage bi
Exclusive licensing of certain of Avicanna’s advanced and evidence-based CBD topical products including its deep tissue and skin care formulations. Heritage to lead medical sales and commercialization across non-competing medical channels in Canada
Congratulations to BAM member XiteBio Technologies Inc.!
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.